Sapogenin PEG Ester Complex for Poorly Water-Soluble Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly water-soluble active ingredients, such as pharmaceutical, dietary, and cosmetic compounds, face challenges in bioavailability due to limited solubility, leading to reduced absorption and therapeutic effectiveness, necessitating high doses that can cause side effects.
Innovation Solution
The development of a Compound of Formula-I, specifically Sapogenin Polyethylene Glycol esters, which enhances solubility and bioavailability by forming a composition with active ingredients, including a method of preparation involving mixing sapogenin with carboxylic acid derivatives and PEG, followed by solvent removal and washing steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of poorly water-soluble ingredients are used to achieve desired therapeutic effect, then therapeutic effectiveness is improved, but side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the physical-chemical properties of poorly water-soluble ingredients through complexation with cyclodextrins. This transformation changes the solubility parameter of the active ingredient, enabling it to dissolve in aqueous environments without altering the therapeutic action of the compound. The complexation process creates a water-soluble inclusion complex that maintains the pharmacological activity while improving bioavailability.
Solution Approach 2:
Cyclodextrins serve as intermediary molecules that mediate between the hydrophobic active ingredient and the aqueous biological environment. The cyclodextrin forms an inclusion complex where the hydrophobic active ingredient is encapsulated within its hydrophobic cavity, while the hydrophilic exterior of the cyclodextrin interacts with water. This intermediary structure enables the delivery of water-insoluble compounds without requiring high doses.
2Quantity of substance
If high doses of poorly water-soluble ingredients are administered, then absorption is improved, but safety profile deteriorates
Solution Approach 1:
The patent modifies the solubility parameter of the active ingredient by forming inclusion complexes with cyclodextrins. This parameter change enables the substance to be absorbed at lower concentrations since it can now dissolve in the aqueous environment of the gastrointestinal tract. The complexation increases the apparent solubility and bioavailability without requiring increased dosing.
Solution Approach 2:
The patent creates a composite system consisting of the active ingredient encapsulated within the cyclodextrin structure. This composite material combines the therapeutic properties of the active ingredient with the solubility-enhancing properties of cyclodextrin. The resulting inclusion complex exhibits both improved absorption characteristics and maintained safety profile.
3Device complexity
If poorly water-soluble ingredients are formulated, then formulation complexity increases, but bioavailability decreases
Solution Approach 1:
Cyclodextrins act as intermediary carriers that simplify the formulation process for water-insoluble ingredients. Rather than requiring complex formulation strategies such as surfactant mixtures, emulsions, or lipid-based systems, the patent uses cyclodextrin complexation as a straightforward approach. The cyclodextrin naturally solubilizes the active ingredient through inclusion complexation, reducing formulation complexity while improving bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Compound of Formula-I significantly improves the solubility and bioavailability of active ingredients, leading to enhanced absorption and therapeutic effects while minimizing side effects associated with high doses.
Implementation Method 1
The present disclosure relates to Compound of Formula-I representing Sapogenin Polyethylene Glycol ester and process of preparation of said Compound of Formula-I
Data Source
AI summary
The present disclosure relates to field of Pharmaceutical Chemistry. The present disclosure particularly relates to Compound of Formula-I and process of preparation of the said Compound of Formula-I. The present disclosure further relates to Composition comprising the Compound of Formula-I and active ingredients, such as active pharmaceutical ingredient, dietary ingredients and cosmetic ingredients. The said composition possesses improved solubility and improved bioavailability for the active ingredients such as active pharmaceutical ingredient, dietary ingredients and cosmetic ingredients.